App-Quantinova.ai

Retention Rate of TNF Inhibitors (TNFi) in Ankylosing Spondylitis (AS) Patients from the Rhumadata Clinical Database and Registry

Denis Choquette - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Ankylosing spondylitis

N/A

First Presentation of Inflammatory Bowel Disease as a Migratory Polyarthritis with Positive C-ANCA and PR3

Ibrahim Almaghlouth - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Leukocytoclastic vasculitis

Prednisone

A Case of TTP in a Patient with MCTD and Elevated ADAMTS13 Antibodies

Natalia Pittman - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Thrombotic thrombocytopenic purpura

Prednisone

Pregnancy Outcomes in Women with Childhood-onset Systemic Lupus Erythematous from a Large Population-based Cohort

Longdi Fu - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

N/A

Is Treat-To-Target Really Working? A Longitudinal Analysis in BIODAM

Maggie Larche - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

Examining Perceived Risk Factors of Arthritis: Findings from a Public Opinion Survey

Tristan Robinson - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

N/A

Toward the Definition of Low Disease Activity in Systemic Lupus Erythematosus

Dafna Gladman - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

N/A

Exploration of Associations between Air Pollutants and Familial or Non Familial Forms of Page-s Disease of Bone

Sonia Jean - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

Pregnancy & Parenting with Arthritis: Bridging the Information Gap

Nathalie Robertson - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Inflammatory Arthritis

N/A

Minimal Disease Activity among Psoriatic Arthritis Patients in Canada: Evaluation of Modified Minimal Disease Activity upon Elimination of Each Component

Proton Rahman - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ankylosing spondylitis

Infliximab

Comparison of Baseline Characteristics of Rheumatoid Arthritis Patients Initiating Therapy with Subcutaneous Golimumab and Infliximab and Intravenous Golimumab: An Analysis from the Prospective, Observational Registry, BioTRAC

Wojciech Olszynski - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ankylosing spondylitis

Infliximab

Baricitinib, an Oral Janus Kinase (JAK)1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to TNF Inhibitors: Results of the Phase 3 RA-BEACON Study

Joel Kremer - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Baricitinib

Retrospective Study of Osteoporosis Management in Patients with Fragility Hip Fracture During Hospitalization in an Acute Care Setting

George Ho - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoporosis

N/A

Comparative Clinical and Cost Analysis of Surgical and Non-Surgical Intervention for Osteoarthritis of the Knee

Caroline Jones - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

N/A

Baricitinib, an Oral Janus Kinase (JAK)1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to cDMARD Therapy: Results of the Phase 3 RA-BUILD Study

Mark Genovese - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Baricitinib

The Impact of Disease-related and Contextual Factors on Work Outcomes in Chronic Inflammatory Arthritis Patients Treated with Biologics: A Systematic Review

Panos Lambiris - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

N/A

Prevalence of Rheumatic Disease Related Medication use in the Sleep Laboratory Population and the Association with Obstructive Sleep Apnea

Meenu Sharma - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Sleep apnoea

Acetaminophen

Dermatomyositis and Hashimoto Thyroiditis

Paul MacMullan - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Autoimmune Thyroid Disease

N/A

To Evaluate the Drug Survival Analysis of First Non-TNF Biologic Agents in Rheumatoid Arthritis Patients

James Ting - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Tocilizumab

Relationship of Sleep and Pain to Fatigue in RA Patients

John Gjevre - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Sleep apnoea

N/A

Filters

28841 Abstracts